PURPOSE: We investigated the possible association of DNA polymorphisms -2548G/A and Q223R in the leptin (LEP) and leptin receptor (LEPR) genes, respectively, which both affect the amount of circulating cytokine-type hormone leptin, with risk for development of oral cancer. METHODS: Polymerase chain reaction-based restriction analysis was performed in DNA samples of 150 patients with oral squamous cell carcinoma (OSCC) and 152 healthy control subjects of equivalent gender, age, and ethnicity (Greeks and Germans). RESULTS: Compared to controls, the homozygous high gene expression genotype A/A of the LEP -2548G/A polymorphism was significantly increased in the subgroups of patients with advanced cancer stages (P = 0.0001; OR 9.0, 95% CI 2.62-30.89), with a positive family history of cancer (P = 0.0346; OR 3.55, 95% CI 1.15-11.01), without tobacco abuse (P = 0.0051; OR 9.69, 95% CI 1.03-91.24), and without alcohol abuse (P = 0.0472; OR 2.16, 95% CI 0.87-5.37). The homozygous low-leptin-binding genotype G/G of the LEPR Q223R polymorphism was strongly associated with an increased risk for OSCC for all patients (P = 0.0028; OR 4.11, 95% CI 1.30-12.97) as well for most of the patient subgroups. CONCLUSIONS: The above findings are consistent with the growth-promoting role of leptin in cancer and its induction effect on angiogenesis and metastasis. This is the first study indicating the association of these LEP and LEPR gene polymorphisms with increased risk for OSCC.
PURPOSE: We investigated the possible association of DNA polymorphisms -2548G/A and Q223R in the leptin (LEP) and leptin receptor (LEPR) genes, respectively, which both affect the amount of circulating cytokine-type hormone leptin, with risk for development of oral cancer. METHODS: Polymerase chain reaction-based restriction analysis was performed in DNA samples of 150 patients with oral squamous cell carcinoma (OSCC) and 152 healthy control subjects of equivalent gender, age, and ethnicity (Greeks and Germans). RESULTS: Compared to controls, the homozygous high gene expression genotype A/A of the LEP-2548G/A polymorphism was significantly increased in the subgroups of patients with advanced cancer stages (P = 0.0001; OR 9.0, 95% CI 2.62-30.89), with a positive family history of cancer (P = 0.0346; OR 3.55, 95% CI 1.15-11.01), without tobacco abuse (P = 0.0051; OR 9.69, 95% CI 1.03-91.24), and without alcohol abuse (P = 0.0472; OR 2.16, 95% CI 0.87-5.37). The homozygous low-leptin-binding genotype G/G of the LEPRQ223R polymorphism was strongly associated with an increased risk for OSCC for all patients (P = 0.0028; OR 4.11, 95% CI 1.30-12.97) as well for most of the patient subgroups. CONCLUSIONS: The above findings are consistent with the growth-promoting role of leptin in cancer and its induction effect on angiogenesis and metastasis. This is the first study indicating the association of these LEP and LEPR gene polymorphisms with increased risk for OSCC.
Authors: S Kurahara; M Shinohara; T Ikebe; S Nakamura; M Beppu; A Hiraki; H Takeuchi; K Shirasuna Journal: Head Neck Date: 1999-10 Impact factor: 3.147
Authors: C T M van Rossum; B Hoebee; J C Seidell; C Bouchard; M A van Baak; C P G M de Groot; M Chagnon; C de Graaf; W H M Saris Journal: Int J Obes Relat Metab Disord Date: 2002-04
Authors: C Yapijakis; E Vairaktaris; S Vassiliou; A Vylliotis; E Nkenke; A M Nixon; S Derka; S Spyridonidou; E Vorris; F Neukam; E Patsouris Journal: J Cancer Res Clin Oncol Date: 2007-06-13 Impact factor: 4.553
Authors: Syed Rizwan Hussain; Hena Naqvi; Shalini Gupta; Abbas Ali Mahdi; Pratibha Kumari; Mohammad Waseem; Mohammad Kaleem Ahmad Journal: Tumour Biol Date: 2015-03-26
Authors: Azza M Abdu Allah; Sally M El-Hefnway; Alshimaa M Alhanafy; Ahmed M Zahran; Heba E Kasem Journal: Mol Cell Biochem Date: 2018-02-16 Impact factor: 3.396